American Society for Radiation Oncology Annual Meeting (ASTRO)

Nikolai Strusberg, MD, discussed other toxicities of proton vs photon breast radiation therapy, practice implications, and next steps in capsular contracture research.

Nikolai Strusberg, MD, explained the clinical hypothyroidism endpoint and how thyroid dose should guide proton vs photon choice in breast cancer.

Leah Katz, MD, MPH, discusses IDEA, TARGIT-B, NeoORB, and other breast radiation data from ASTRO 2026, and why patient selection is the unifying theme.

Nikolai Strusberg, MD, discussed how proton therapy reduced clinical hypothyroidism vs photon therapy after supraclavicular breast irradiation.

Leah Katz, MD, MPH, discussesed NeoORB data on neoadjuvant radiotherapy and why radiation timing may open new treatment paradigms in breast cancer.

Leah Katz, MD, MPH, explained how an intraoperative tumor bed boost in TARGIT-B may reduce distant relapse in young patients with breast cancer.

Leah Katz, MD, MPH, discusses long-term IDEA trial data on omitting radiation and why endocrine therapy tolerance matters in this decision.

Alexandra Dreyfuss, MD, MS, explains why CAR T and bispecific populations are her priority for prospective radiotherapy studies in multiple myeloma.

There is a gap in prospective data for radiation use in multiple myeloma, according to Alexandra Dreyfuss, MD, MS.

Nikolai Strusberg, MD, discussed how proton therapy and thyroid dose affect clinical hypothyroidism risk after supraclavicular breast radiation.

Brandon Mancini, MD, MBA, FACRO, discusses the presentations from ASTRO 2026 that may impact the future of prostate cancer, lung cancer, and other diseases.

Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.

“What we have here, I believe, is a strong signal that there is a population…who will benefit from chemotherapy,” said Mark D. Hurwitz, MD, FASTRO, FACRO.

Nitin Ohri, MD, MS, explains the rationale for combining thoracic radiotherapy with dual PD-1 and LAG-3 blockade in locally advanced NSCLC.

At the 2026 ASTRO Annual Meeting, Marcio A. Fagundes, MD, discussed when proton therapy is most justified over photon approaches in prostate cancer.

Ayal Aizer, MD, MHS, discussed Alliance A071801 trial data favoring fractionated SRS over single-fraction SRS after brain metastasis resection.

Marcio A. Fagundes, MD, explained how proton therapy and rectal spacers can reduce radiation exposure to the rectum, bowel, and bladder in prostate cancer.

Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.

In the phase 3 Alliance A071801 trial, postoperative fractionated SRS improved surgical bed control vs single-fraction SRS without added toxicity.

William A. Hall, MD, reviews resection rates, surgical complications, and SBRT target volumes from the SOFT Preop study in pancreatic cancer.

William A. Hall, MD, explains how fewer visits, no concurrent chemotherapy, and adaptive MRI guidance may have preserved quality of life with SBRT.

“We are not just treating the cancer; we are treating the patient,” said Marcio A. Fagundes, MD.

William A. Hall, MD, discussed how preoperative SBRT may serve as a platform for novel systemic therapies in pancreatic adenocarcinoma.

At 8 years, SBRT and radical prostatectomy had similar disease control in the PACE-A trial, with less urinary incontinence after SBRT.

An aglatimagene besadenovec-based radiotherapy combination increased intratumoral lymphocyte fraction in intermediate- to high-risk localized prostate cancer.

William A. Hall, MD, discussed the SOFT Preop study of preoperative SBRT vs conventional chemoradiation for pancreatic adenocarcinoma.

Ayal Aizer, MD, MHS, discusses patients for whom single-fraction SRS may remain reasonable after brain metastasis resection.

The phase 3 NRG-GI003 trial showed no overall survival benefit with proton therapy over photon therapy in patients with advanced hepatocellular carcinoma.

10-year CHN HYPOPMRT data show 3-week postmastectomy RT with nodal irradiation maintains locoregional control without added severe late toxicity.

Ayal Aizer, MD, MHS, explains why fractionated SRS outperformed single-fraction SRS for surgical bed control in Alliance A071801.